COVID-19 pandemic and vaccination rate in patients with psoriasis treated with biologics: A single center experience
Background/Aim. Psoriasis is a chronic, immune-mediated, genetically determined disease, which is manifested by the appearance of erythematous scaly plaques. Treatment includes conventional therapies and biologics. The coronavirus disease 2019 (COVID-19) raised widespread concern for patients with p...
Saved in:
Main Authors: | Milčić Danijela, Malinić Marija, Ćirković Anđa, Krupniković Doroteja, Milinković-Srećković Mirjana |
---|---|
Format: | Article |
Language: | English |
Published: |
Military Health Department, Ministry of Defance, Serbia
2024-01-01
|
Series: | Vojnosanitetski Pregled |
Subjects: | |
Online Access: | https://doiserbia.nb.rs/img/doi/0042-8450/2024/0042-84502400083M.pdf |
Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Similar Items
-
Efficacy and safety of ustekinumab in the treatment of moderate to severe plaque psoriasis in Singapore
by: Wai Sze Agnes Chan, et al.
Published: (2023-07-01) -
Managing pediatric psoriasis: update on treatments and challenges—a review
by: A. A. Hebert, et al.
Published: (2022-07-01) -
Biological therapy in the reduction of cardiovascular risk in patients with psoriasis
by: Andrés Tirado-Sánchez
Published: (2025-01-01) -
Lack of reactivation of tuberculosis in patients with psoriasis treated with secukinumab in a real-world setting of latent tuberculosis infection
by: Matteo Megna, et al.
Published: (2022-07-01) -
Ten-Year Persistence of Biologic Drugs in Psoriasis and Its Relationship with Pharmacogenetic Biomarkers
by: Andrea Rodríguez-Lopez, et al.
Published: (2024-12-01)